Watch for Ibsrela for Irritable Bowel Syndrome

June 2022

New Rx Ibsrela (tenapanor) will soon hit shelves for irritable bowel syndrome with constipation (IBS-C) in adults.

You’ll hear that Ibsrela is the first “NHE3 (sodium/hydrogen exchanger 3) inhibitor” for IBS-C.

It’s touted to have a “triple action” that blocks dietary sodium absorption...improves leaky gut...and reduces visceral hypersensitivity, or pain-sensing nerve activity in the GI tract.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Aspirin Clear Up Confusion About Aspirin for CV Primary Prevention
Bites & Stings Answer Questions About Insect and Tick Repellents
Heart Failure Clarify New Heart Failure Terms and Management
Psychiatry Use a Practical Approach to Manage Agitation in Dementia
Med Safety Put PDE5 Inhibitor Risks in Perspective
Insomnia Quell Hype About New Quviviq for Insomnia
Travel Medicine Share Strategies to Prevent Blood Clots When Traveling
Cancer Help Overcome Barriers to Opioid Use for Cancer Pain
IBS Watch for Ibsrela for Irritable Bowel Syndrome

Watch for Ibsrela for Irritable Bowel Syndrome

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Table of Contents